FT-522
- Generic Name
- FT-522
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory B-Cell Lymphoma
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 166
- Registration Number
- NCT05950334
- Locations
- 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath